Recently, Zhuhai United Laboratories Bio-Pharmaceutical Co., Ltd. (“United Bio-pharma”) and the Department of Pharmacy of Beijing Tsinghua Changgung Hospital officially established an industry–university–research collaboration. Both parties will fully leverage their respective strengths in biopharmaceutical innovation and clinical medical research to jointly develop high-performance moisturizing creams and related products targeting dry skin conditions associated with chronic and recurrent dermatological diseases such as atopic dermatitis, while also advancing their translational production and application.

Skin diseases affect hundreds of millions of people worldwide, with chronic conditions such as atopic dermatitis and eczema being particularly common. These conditions not only cause persistent itching, redness and discomfort, but also subtly impact patients’ confidence and social lives. The health of the skin is closely linked to both outward appearance and inner well-being.

For these conditions, both scientific medical treatment and daily care are equally important. Modern dermatology emphasizes that, alongside timely medical consultation and standardized pharmacological treatment, a “treatment plus care” approach should be adopted, integrating moisturizing skincare products into the overall management plan. These dermatology-informed moisturizing products are designed based on skin science principles and provide supportive care functions such as hydration, barrier repair and soothing effects. They help nourish dry and damaged skin, relieve itching and discomfort, and gradually improve skin condition in daily life, allowing patients to experience a sense of comfort and reassurance through consistent care.

Beijing Tsinghua Changgung Hospital is a large comprehensive public hospital jointly established and co-managed by Tsinghua University and the Beijing Municipal Government. The hospital upholds a patient-centered approach to medical services, a physician-centered model for hospital operations, and an employee-focused philosophy for institutional development. It has established and actively practices the “Three-P Precision Medicine” concept—Precision Medicine, Precise Service, and Lean Management—building a modern healthcare service system that integrates digital intelligence and covers the entire life cycle of health management.

The hospital has developed a strong multidisciplinary structure comprising more than 50 clinical and medical technology departments, forming a robust academic and clinical system. It has established a number of outstanding specialties, including Endocrinology and Metabolism, Rheumatology and Immunology, Dermatology and Pharmacy. In addition, the hospital has implemented over 100 leading medical technologies recognized domestically and internationally, achieving multiple world-record milestones in clinical practice and innovation.

Zhuhai United Laboratories Bio-Pharmaceutical Co., Ltd. is a core biopharmaceutical R&D entity under United Laboratories, focusing on the research, development, manufacturing, and commercialization of innovative biologics in areas such as diabetes, weight management and autoimmune diseases. The company has successfully developed a range of insulin products and GLP-1 class drugs, aiming to provide high-quality biopharmaceutical solutions for patients worldwide. In addition, over the years, United Bio-pharma has invested significant R&D resources in cosmetic raw materials, skin health management and medical aesthetic products. It has developed multiple categories of advanced materials, including synthetic peptide ingredients, recombinant cosmetic raw materials, full-length recombinant collagen for injection use, and anti-Cutibacterium acnes protein-based raw materials. The company has also established GMP-compliant modern production lines, including a 10-ton-scale collagen production line and a dedicated medical aesthetic formulation manufacturing line.

This collaboration represents a new exploration in medical–enterprise innovation. Both parties will leverage their complementary strengths to translate clinical research outcomes into high-quality skincare products, achieving a fully integrated “clinical–R&D–application” closed loop. It serves as an exemplary case of transforming medical theory into practical solutions for the prevention and care of skin diseases.

United Bio-pharma and Beijing Tsinghua Changgung Hospital will remain committed to their original mission, integrating medical expertise with pharmaceutical craftsmanship. Together, they will continue to develop professional, safe and effective skincare products, harnessing the power of science to safeguard skin health.